Antiviral treatment associated with reduced risk of clinical Alzheimer's disease: A nested case-control studyVisa övriga samt affilieringar
2021 (Engelska)Ingår i: Alzheimer’s & Dementia: Translational Research & Clinical Interventions, E-ISSN 2352-8737, Vol. 7, nr 1, artikel-id e12187Artikel i tidskrift (Refereegranskat) Published
Abstract [en]
Introduction: In this nested case-control study, we investigated if antiviral treatment given prior to onset of Alzheimer's disease (AD) could influence incident AD.
Methods: From a large population-based cohort study in northern Sweden, 262 individuals that later developed AD were compared to a non-AD matched control group with respect to prescriptions of herpes antiviral treatment. All included subjects were herpes simplex virus 1 (HSV1) carriers and the matching criteria were age, sex, apolipoprotein E genotype (ε4 allele carriership), and study sample start year.
Results: Among those who developed AD, 6 prescriptions of antivirals were found, compared to 20 among matched controls. Adjusted for length of follow-up, a conditional logistic regression indicated a difference in the risk for AD development between groups (odds ratio for AD with an antiviral prescription 0.287, P = .018).
Discussion: Antiviral treatment might possibly reduce the risk for later development of HSV1-associated AD.
Ort, förlag, år, upplaga, sidor
John Wiley & Sons, 2021. Vol. 7, nr 1, artikel-id e12187
Nyckelord [en]
Alzheimer’s disease, antiviral treatment, apolipoprotein E gene, dementia, herpes simplex, major neurocognitive disorder, nested case-control study
Nationell ämneskategori
Geriatrik
Identifikatorer
URN: urn:nbn:se:umu:diva-187310DOI: 10.1002/trc2.12187ISI: 000750546300053Scopus ID: 2-s2.0-85114262531OAI: oai:DiVA.org:umu-187310DiVA, id: diva2:1591999
Forskningsfinansiär
Region VästerbottenDemensförbundetAlzheimerfondenKnut och Alice Wallenbergs StiftelseForte, Forskningsrådet för hälsa, arbetsliv och välfärd, 2013-20562021-09-072021-09-072026-08-10Bibliografiskt granskad